Pharmacogenomics: The Future of ADHD Treatment Options
Researchers from universities around the world conducted a meta-analysis of genome-wide association studies to explore genes that could be potential targets for pharmacologic therapy of Attention-Deficit Hyperactivity Disorder (ADHD), and its comorbidities. The comorbidities included in the study fell into 3 categories: cardiovascular, immune, and neuropsychiatric. The study results were published in the journal Molecular Psychiatry.
Other Articles in this Edition
Artificial intelligence boosts MRI detection of ADHD
Pharmacogenomics: The Future of ADHD Treatment Options
Largest study of its kind reveals that many psychiatric disorders arise from common genes
Young children exposed to nicotine may develop hyperactivity, conduct problems
Young Adults with ADHD are At Higher Risk for Developing Nicotine Addiction
Comparing Rates of ADHD Diagnosis Across Doctors